Download presentation
Presentation is loading. Please wait.
Published byElaine Russell Modified over 9 years ago
1
SARC020 – EORTC 62091 TRUSTS – A phase IIb/III multicenter study comparing the efficacy of TRabectedin administered as a 3-hour or 24-hour infusion to doxorubicin in patients with advanced or metastatic Untreated Soft Tissue Sarcoma Study PI: James Butrynski, MD Dana Farber Cancer Institute/SARC Binh Bui, MD Institut Bergonie/EORTC
2
Primary Objective To determine whether trabectedin given as 1 st line chemotherapy for advanced/metastatic soft tissue sarcoma prolongs progression free survival, as compared to doxorubicin. © All Rights Reserved
3
Secondary End Points Overall survival Response rate and response duration Quality of Life Adverse Events/Safety Profile © All Rights Reserved
4
Study design Randomized phase II b / III trial
5
Inclusion Criteria Histologically proven advanced and/or metastatic malignant soft tissue sarcoma of intermediate/high grade not previously treated (see protocol Appendix B) Excluded: WD liposarcoma, embryonal rhabdomyosarcoma, Ewing’s, GIST, DFSP Paraffin blocks or representative H/E slides must be available for histological central review Confirmed disease progression – investigator judgment Presence of measureable disease according to RECIST 1.1 No anti-cancer therapy or other investigational agents within 28 days prior to treatment start Adequate organ function as defined by protocol WHO performance status 0 or 1 At least 18 years old © All Rights Reserved
6
Exclusion Criteria History of CNS metastases or leptomeningeal tumor spread Prior treatment with anthracyclines for advanced or metastatic STS Women who are pregnant or breastfeeding Active/uncontrolled infections or medical conditions, including history of chronic alcohol abuse, hepatitis, HIV and cirrhosis History within past five years of malignancies other than STS (see protocol Section 3 Patient Selection Criteria for exceptions) © All Rights Reserved
7
SARC020 Study Status Total Sites Activated:US – 7 Sites / 10 EU – 19 Sites / 37 TOTAL : 25/47 Total Patients Enrolled:US – 21 Patients EU – 112 Patients Current Status:Accrual for Step 1 completed; enrollment on hold as of 8/6/2012 for interim analysis
8
SARC020 Participating Centers US 7 Open sites in US: Carolina’s Hematology Oncology Associates Dana-Farber Cancer Institute Nebraska Methodist Hospital Pennsylvania Oncology Hematology Associates Sarcoma Oncology Center Stanford University of Iowa Sites in progress: Washington University University of Pittsburgh Cedars Sinai
9
Recruitment / Country Trabectedin 3 hrsTrabectedin 24 hrsDoxoTotal France16141646 The Netherlands43411 U.S.A26210 Germany3249 Austria2--2 Spain1-12 Total28252780
10
Translational research program Predictive value of molecular markers Identify / validate biomarkers of sensitivity to trabectedin and doxorubicin Focus on proteins related to the mechanism of action of trabectedin DNA repair proteins Key genes in the development / prognosis of sarcoma subtypes. FFPE or unstained slides from initial diagnosis Material collected for the confirmation of diagnosis Technique: IHC with guidelines from PharmaMar Optional (additional IC required) Must be proposed to all patients
11
Recrutment / Center Trabectedi n 3 hrs Trabectedin 24 hrsDoxoTotal 227.Centre Léon Bérard (FR) 1113 228.Institut Bergonie (FR) 45514 229.Centre G.F.Leclerc (FR) 3148 234.Centre Oscar Lambret (FR) 44412 235.Centre R.Gauducheau (FR) 1-12 259.H.Necker-I.Curie (FR) 2-13 287.C.H.U. De La Timone (FR) 13-4 301.N.K.I / A.V.L. A'Dam (NL) 1124 302 Erasmus MC R’Dam (NL) 11-2 310 UMC Leiden (NL) 1--1 3039.Un.C.G.C. Dresden (DE) 1113 335.UMCG (NL) 1124 527.Univ. Mannheim (DE) 1113 906. Med Univ. Vienna (AU) 2--2 8673.Univ Of Iowa Hosp (US) 1326 9178.Sarcoma Onco Cter (US) -2-2 9361.Carolinas MC (US) 11-2 Total28252780
12
RECIST 1.1 (1) Measurable disease: Presence of at least one measurable lesion. If the measurable disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology/histology
13
SARC020 Participating Centers EU Austria Medical University Vienna - General Hospital France Centre Leon Berard Centre Georges-Francois-Leclerc Institut Bergonie Centre Oscar Lambret Institut de Cancerologie de l’Ouest (ICO) – Centre Rene Gauducheau Institut Curie Assistance Publique - Hôpitaux de Marseille – Hôpital de La Timone Germany Universitaetsklinikum Koeln UniversitaetsMedizin Mannheim Universitaetsklinikum Carl Gustav Carus Klinikum Grosshadern Ludwig-Maximilians Univ. Muenchen The Netherlands The Netherlands Cancer Institute – Antoni Van Leeuwenhoekziekenhuis Erasmus MC - Daniel den Hoed Cancer Center Leiden University Medical Centre University Medical Center Groningen Spain Hospital General Vall D'Hebron Switzerland Centre Hospitalier Universitaire Vaudois UK Christie NHS Foundation Trust
14
Accrual on 14/03/2012 Accrual graph for step 1 Institution Number of patients 228.Institut Bergonie (FR)12 234.Centre Oscar Lambret (FR) 11 229.Centre G.F.Leclerc (FR)5 8673.Univ Of Iowa Hosp (US)4 259.H.Necker-I.Curie (FR)3 287.C.H.U. De La Timone (FR) 3 335.UMCG (NL)3 235.Centre R.Gauducheau (FR) 2 527.Univ. Mannheim (DE)2 9178.Sarcoma Onco Cter (US) 2 9361.Carolinas MC (US)2 301.N.K.I / A.V.L. A'Dam (NL)1 3039.Un.C.G.Carus Dresden (DE) 1 371.Hosp. Vall D'Hebron (ES) 1 906.Med Univ Vienna (AT)1 Total53
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.